12/21
07:42 am
pvla
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
High
Report
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin [Yahoo! Finance]
12/20
09:41 pm
pvla
Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]
High
Report
Assessing Palvella Therapeutics' Valuation After Its Rare Disease Momentum-Driven Surge in 2024 [Yahoo! Finance]
12/16
10:55 am
pvla
Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]
Medium
Report
Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer [Yahoo! Finance]
12/16
09:11 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $204.00 price target on by analysts at Canaccord Genuity Group Inc..
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $204.00 price target on by analysts at Canaccord Genuity Group Inc..
12/16
09:08 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $97.00 to $133.00. They now have a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its price target raised by analysts at TD Cowen from $97.00 to $133.00. They now have a "buy" rating on the stock.
12/16
08:43 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "strong-buy" rating reaffirmed by analysts at Raymond James Financial, Inc..
12/16
08:04 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/16
07:30 am
pvla
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
Medium
Report
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
12/15
07:02 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at BTIG Research.
12/15
07:01 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $174.00 price target on by analysts at Chardan Capital.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $174.00 price target on by analysts at Chardan Capital.
12/15
04:05 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
12/15
03:05 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/15
02:05 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $200.00 price target on by analysts at HC Wainwright.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $200.00 price target on by analysts at HC Wainwright.
12/15
11:08 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
12/15
06:15 am
pvla
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
High
Report
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
12/15
06:00 am
pvla
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
High
Report
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approve
12/11
10:04 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/10
04:10 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
12/9
08:11 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
12/6
05:47 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Craig Hallum to a "strong-buy" rating.
12/5
07:21 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Medium
Report
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
12/4
08:04 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) is now covered by analysts at Craig Hallum. They set a "buy" rating on the stock.
11/26
02:13 pm
pvla
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
07:19 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was given a new $145.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Palvella Therapeutics (NASDAQ:PVLA) was given a new $145.00 price target on by analysts at Stifel Nicolaus.
11/19
08:07 am
pvla
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $143.00 price target on the stock, up previously from $92.00.
High
Report
Palvella Therapeutics (NASDAQ:PVLA) was upgraded by analysts at Raymond James Financial, Inc. from an "outperform" rating to a "strong-buy" rating. They now have a $143.00 price target on the stock, up previously from $92.00.